Journal
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
Volume 42, Issue 9, Pages 2321-2329Publisher
WILEY
DOI: 10.1002/hed.26201
Keywords
insurance claims review; lifetime cost; oropharyngeal cancer
Categories
Funding
- Christopher and Susan Damico Chair in Viral Associated Malignancies at The University of Texas MD Anderson Cancer Center
- Lyda Hill Foundation
- Cancer Prevention and Research Institute of Texas (CPRIT) [RP170259]
- Stiefel Oropharyngeal Research Fund
Ask authors/readers for more resources
Background Incidence of oropharyngeal cancer (OPC) is expected to increase but its health care cost is unknown. The purpose for this study was to estimate the phase-specific lifetime health care costs of OPC for commercially insured individuals in the United States. Methods We used the Truven MarketScan Commercial Claims and Encounter Database to identify our patient population. Cox survival analysis was used to estimate patients' monthly survival probabilities. We determined the ratios of the cumulative costs up to a particular survival probability and the costs from that time point to death for all subjects who died before end of the 5-year follow-up period. This relationship was then used to predict phase-specific lifetime health care costs. Results Our study included 2445 patients with OPC. The predicted phase-specific lifetime health care costs attributable to OPC were $88 872, $24 038, and $1537 in the initial, continuous, and terminal phases, respectively, among commercially insured patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available